Clinical trials: Oral Cavity Carcinoma
Oral Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
Carrimycin in Patients With Locally Advanced, Recurrent, or Metastatic HNSCC (Non NPC): A Phase I Trial
The trial is a study conducted to evaluate the safety, tolerability and PK characteristics of Carrimycin tablet and measure its anti-tumor efficacy initially in the treatment of patients with locally advanced, recurrent, or…
- Trial name
- NCT04413214
- Testing
- Carrimycin
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Carcinoma, Non-Small-Cell Lung Cancer
Study of Oral cMET Inhibitor INC280 in Chinese Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (NSCLC)
A phase II study to evaluate antitumor activity of oral cMET inhibitor INC280 in adult Chinese patients with EGFR wild-type, advanced non-small cell lung cancer (NSCLC) who have received one or two prior lines of systemic therapy…
- Trial name
- NCT03240393
- Testing
- INC280
- Sponsor
- Novartis Pharmaceuticals
Head and Neck Cancer, Oropharyngeal Squamous Cell Carcinoma
Radiotherapy vs. Trans-Oral Surgery for HPV-Negative Oropharyngeal Squamous Cell Carcinoma
The goal of this randomized phase II study is a formal comparison of radiotherapy versus trans-oral surgery as the primary treatment of HPV-negative patients with early-stage oropharyngeal carcinoma.
- Trial name
- NCT04220749
- Testing
- Radiation, Trans-Oral Surgery (TOS) + Neck Dissection
- Where
- Canada
- Volunteers
- 68 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Oral Cancer, Oropharynx Cancer
Accelerated Radiotherapy and Concomitant Chemo-radiotherapy in HNSCC
This is a multicentric randomized phase III trial comparing conventional radiotherapy with concomitant chemotherapy versus accelerated radiotherapy with concomitant chemotherapy versus very accelerated radiotherapy in patients…
- Conditions
- Oral Cancer, Oropharynx Cancer, Hypopharynx Cancer, Larynx Cancer
- Trial name
- NCT00158652
- Testing
- Conventional radiotherapy 70 Gy in 7 weeks, middle accelerated radiotherapy 70 Gy in 6 weeks, very accelerated radiotherapy 64.8 Gy in 3.5 weeks
- Where
- 2 sites in France
- Volunteers
- 840 people
- Sponsor
- Groupe Oncologie Radiotherapie Tete et Cou
Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Oropharynx
Photodynamic Therapy With HPPH in Treating Patients With Squamous Cell Carcinoma of the Oral Cavity
This randomized phase II trial studies how well photodynamic therapy with HPPH works in treating patients with squamous cell carcinoma of the oral cavity.
- Conditions
- Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity
- Trial name
- NCT02119728
- Testing
- HPPH, Light Infusion Therapy™, therapeutic conventional surgery
- Where
- United States
- Sponsor
- Roswell Park Cancer Institute
Head and Neck Cancer
Collecting and Storing Tissue Samples From Patients With Head and Neck Cancer
RATIONALE: Collecting and storing samples of tissue, blood, and saliva from patients with cancer to study in the laboratory may help the study of cancer in the future.
- Trial name
- NCT00898300
- Testing
- biologic sample preservation procedure, biopsy
- Where
- 98 sites in United States, Canada
- Volunteers
- 351 people
- Sponsor
- Radiation Therapy Oncology Group
Oral Squamous Cell Carcinoma, Locally Advanced Head and Neck Carcinoma
Neoadjuvant Immunochemotherapy for LAOSCC
To evaluate the prognostic efficacy of neoadjuvant immunochemotherapy with tislelizumab, albumin paclitaxel and cisplatin followed by radical surgery and adjuvant therapy compared with standard therapy for patients with locally…
- Trial name
- NCT06258811
- Testing
- albumin paclitaxel, cispatin, tislelizumab
- Where
- China
- Volunteers
- 134 people
- Sponsor
- Lai-ping Zhong
Non-Small Cell Lung Cancer
A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification
The purpose of this study was to determine the maximum tolerated dose (MTD) or recommended phase II dose (RP2D) of INC280 in combination with erlotinib in the Phase Ib of this study, and to assess the anti-tumor activity and…
- Trial name
- NCT02468661
- Testing
- INC280 single agent, erlotinib
- Where
- 32 sites in United States, Belgium and 8 more
- Volunteers
- 23 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Non Small Cell Lung Cancer, Advanced (Inoperable) Non Small Cell Lung Cancer
Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)
This is a 2 part study in patients with EGFRm+ non small cell lung cancer (NSCLC), whose disease has progressed on an EGFRm TKI, who are refractory or resistant to standard therapy.
- Trial name
- NCT02157883
- Testing
- Pharmacokinetic sampling, AZD9291, Itraconazole
- Where
- 16 sites in United States, Belgium and 4 more
- Volunteers
- 39 people
- Sponsor
- AstraZeneca
Carcinoma, Non-Small-Cell Lung, Mesothelioma
Pharmacokinetic, Safety, and Efficacy Effects of Oral LBH589 on Dextromethorphan in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer or Malignant Pleural Mesothelioma
This study will investigate the effect of oral LBH589 on dextromethorphan, a CYP2D6 substrate, and to assess safety and efficacy of oral LBH589 when used with this co-medication in advanced stage NSCLC or malignant pleural…
- Trial name
- NCT00535951
- Testing
- LBH589
- Where
- 5 sites in United States, Canada
- Volunteers
- 18 people
- Sponsor
- Novartis Pharmaceuticals
Head and Neck Cancer
Liposomal Lurtotecan in Treating Patients With Metastatic or Locally Recurrent Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of liposomal lurtotecan in treating patients who have…
- Trial name
- NCT00022594
- Testing
- liposomal lurtotecan
- Where
- 20 sites in Austria, Belgium and 8 more
- Volunteers
- 50 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Cervical Cancer, Fallopian Tube Cancer
Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors
RATIONALE: Immunotoxins can locate tumor cells and kill them without harming normal cells. Immunotoxin therapy may be effective in treating advanced solid tumors.
- Conditions
- Cervical Cancer, Fallopian Tube Cancer, Head and Neck Cancer, Lung Cancer
- Trial name
- NCT00066651
- Testing
- SS1(dsFv)-PE38 immunotoxin
- Where
- 2 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Castration-Resistant Prostatic Cancer, Androgen-Independent Prostatic Cancer
A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors
Study CP-MGC018-03 is an open-label, two-part, Phase 2 study. Part 1 of the study will enroll participants with metastatic castration-resistant prostate cancer (mCRPC) previously treated with one prior androgen receptor…
- Conditions
- Castration-Resistant Prostatic Cancer, Androgen-Independent Prostatic Cancer, Androgen-Insensitive Prostatic Cancer, Androgen-Resistant Prostatic Cancer
- Trial name
- Tamarack (NCT05551117)
- Testing
- vobramitamab duocarmazine 2.0 mg (Arm A), vobramitamab duocarmazine 2.7 mg (Arm B), vobramitamab duocarmazine
- Where
- 63 sites in United States, Australia and 7 more
- Volunteers
- 192 people
- Sponsor
- MacroGenics
Oral Squamous Cell Carcinoma, Locally Advanced Head and Neck Squamous Cell Carcinoma
TPExtreme Induced Chemotherapy Followed by Surgery and Radiotherapy in the Oral Carcinoma.
Research shows that most oral cancer patients are already locally advanced when first diagnosed. Even after surgery and radiation, nearly half of patients develop recurrence or metastasis.
- Trial name
- NCT05872880
- Testing
- Modified radical surgery, Radical surgery
- Where
- China
- Volunteers
- 124 people
- Sponsor
- Xiangya Hospital of Central South University
Head and Neck Cancer
Biomakers in Tissue Samples From Patients With Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck Previously Treated With Cisplatin With or Without Cetuximab
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT01192750
- Testing
- immunohistochemistry staining method, laboratory biomarker analysis, medical chart review
- Volunteers
- 79 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Carcinoma, Non-Small-Cell Lung
An Dose Escalation Trial of Oral BIBF 1120 in Combination With Intravenous Carboplatin and Vinorelbine in Elderly Patients With Advanced Non-Small Cell Lung Cancer - Stage IV (VENUS-2)
To investigate the maximum tolerated dose of BIBF 1120 and safety in escalating doses administered with Vinorelbine i.v. and Carboplatin i.v. in elderly patients with advanced Non-Small Lung Cancer (Stage IV).
- Trial name
- VENUS-2 (NCT01683682)
- Testing
- BIBF 1120, Vinorelbine, Carboplatin
- Where
- 2 sites in Germany
- Volunteers
- 8 people
- Sponsor
- Aktion Bronchialkarzinom e.V.
Medullary Thyroid Cancer, Infantile Myofibromatosis
A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors
This is an open-label, multi-center Phase 1/2 study of oral LOXO-292 in pediatric participants with an activating rearranged during transfection (RET) alteration and an advanced solid or primary CNS tumor.
- Conditions
- Medullary Thyroid Cancer, Infantile Myofibromatosis, Infantile Fibrosarcoma, Papillary Thyroid Cancer
- Trial name
- LIBRETTO-121 (NCT03899792)
- Testing
- Selpercatinib
- Where
- 26 sites in United States, Australia and 9 more
- Volunteers
- 36 people
- Sponsor
- Eli Lilly and Company
Breast Cancer, Colorectal Cancer
Validation of a Screening Tool in Geriatric Oncology
RATIONALE: A screening questionnaire may help doctors plan better treatment for older patients with cancer. PURPOSE: This clinical trial is studying a questionnaire in screening older patients with cancer.
- Conditions
- Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer
- Trial name
- ONCODAGE (NCT00963911)
- Testing
- Geriatric screening tests, Multidimensional geriatric assessment
- Where
- France
- Volunteers
- 1,674 people
- Sponsor
- Institut Bergonié
Squamous Cell Carcinoma
Human Papillomavirus on Oral Tissue, Saliva and Serum
Human papillomavirus (HPV) is one of the most prevalent infections in the world with several millions of new cases diagnosed yearly.
- Trial name
- CDHPOTSS (NCT01043328)
- Where
- Brazil
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- UPECLIN HC FM Botucatu Unesp
Head and Neck Cancer
AP5346 or Oxaliplatin in Treating Patients With Metastatic and/or Unresectable Recurrent Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy, such as AP5346 and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00415298
- Testing
- DACH polymer platinate AP5346, oxaliplatin, gene expression analysis
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of California, San Diego
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.